To systematically review the literature on anti-inflammatory medications for treating pediatric obstructive sleep apnea and perform meta-analysis of the available data.
Data Sources
PubMed/MEDLINE and 4 additional databases.
Review Methods
Three authors independently and systematically searched through June 28, 2018, for studies that assessed anti-inflammatory therapy for treatment of pediatric obstructive sleep apnea (OSA). Data were compiled and analyzed using Review Manager 5.3 (Nordic Cochrane Centre).
Results
After screening 135 studies, 32 were selected for review with 6 meeting inclusion criteria. In total, 668 patients aged 2 to 5 years met inclusion criteria for meta-analysis. Of these, 5 studies (166 children) that evaluated montelukast alone as treatment for pediatric OSA found a 55% improvement in the apnea-hypopnea index (AHI) (mean [SD] 6.2 [3.1] events/h pretreatment and 2.8 [2.7] events/h posttreatment; mean difference [MD] of −2.7 events/h; 95% confidence interval [CI], –5.6 to 0.3) with improvement in lowest oxygen saturation (LSAT) from 89.5 (6.9) to 92.1 (3.6) (MD, 2.2; 95% CI, 0.5-4.0). Two studies (502 children) observing the effects of montelukast with intranasal corticosteroids on pediatric OSA found a 70% improvement in AHI (4.7 [2.1] events/h pretreatment and 1.4 [1.0] events/h posttreatment; MD of −4.2 events/h; 95% CI, –6.3 to −2.0), with an improvement in LSAT from 87.8 (3.1) to 92.6 (2.2) (MD, 4.8; 95% CI, 4.5-5.1).
Conclusions
Treatment with montelukast and intranasal steroids or montelukast alone is potentially beneficial for short-term management of mild pediatric OSA.
MarcusCLBrooksLJDraperKAet al. Diagnosis and management of childhood obstructive sleep apnea syndrome. Pediatrics. 2012;130:e714-e755.
3.
Kheirandish-GozalLBhattacharjeeRBandlaHPRet al. Antiinflammatory therapy outcomes for mild OSA in children. Chest. 2014;146:88-95.
4.
TanHLGozalDKheirandish-GozalL. Obstructive sleep apnea in children: a critical update. Nat Sci Sleep. 2013;5:109-123.
5.
CapdevilaOSKheirandish-GozalLDayyatEet al. Pediatric obstructive sleep apnea: complications, management, and long-term outcomes. Proc Am Thorac Soc. 2008;5:274-282.
6.
BhattacharjeeRKheirandish-GozalLSpruytKet al. Adenotonsillectomy outcomes in treatment of obstructive sleep apnea in children: a multicenter retrospective study. Am J Respir Crit Care Med. 2010;182:676-683.
7.
LehmannKJNelsonRMacLellanDet al. The role of adenotonsillectomy in the treatment of primary nocturnal enuresis in children: a systematic review. J Pediatr Urol. 2018;14:53.e1-53.e8.
8.
MitchellRBKellyJ. Outcome of adenotonsillectomy for obstructive sleep apnea in obese and normal-weight children. Otolaryngol Head Neck Surg. 2007;137:43-48.
9.
GallagherTQWilcoxLMcGuireEet al. Analyzing factors associated with major complications after adenotonsillectomy in 4776 patients: comparing three tonsillectomy techniques. Otolaryngol Head Neck Surg. 2010;142:886-892.
10.
RandallDAHofferME. Complications of tonsillectomy and adenoidectomy. Otolaryngol Head Neck Surg. 1998;118:61-68.
11.
SchneuerFJBentleyJPDavidsonAJet al. The impact of general anesthesia on child development and school performance: a population-based study. Paediatr Anaesth. 2018;28:528-536.
12.
CastellheimALundstromSMolinMet al. The role of general anesthesia on traits of neurodevelopmental disorders in a Swedish cohort of twins. J Child Psychol Psychiatry. 2018;59:966-972.
13.
Jevtovic-TodorovicV. Exposure of developing brain to general anesthesia: what is the animal evidence?Anesthesiology. 2018;128:832-839.
14.
ImanguliMUlualpSO. Risk factors for residual obstructive sleep apnea after adenotonsillectomy in children. Laryngoscope. 2016;126:2624-2629.
15.
DayyatESerperoLDKheirandish-GozalLet al. Leukotriene pathways and in vitro adenotonsillar cell proliferation in children with obstructive sleep apnea. Chest. 2009;135:1142-1149.
16.
MoherDLiberatiATetzlaffJet al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006-1012.
17.
HigginsJPThompsonSGDeeksJJet al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
18.
LauJIoannidisJPSchmidCH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127:820-826.
SunkonkitKSritippayawanSVeeravikromMet al. Urinary cysteinyl leukotriene E4 level and therapeutic response to montelukast in children with mild obstructive sleep apnea. Asian Pac J Allergy Immunol. 2017;35:233-238.
21.
YangDZLiangJZhangFet al. Clinical effect of montelukast sodium combined with inhaled corticosteroids in the treatment of OSAS children. Medicine (Baltimore). 2017;96:e6628.
22.
GoldbartADGoldmanJLVelingMCet al. Leukotriene modifier therapy for mild sleep-disordered breathing in children. Am J Respir Crit Care Med. 2005;172:364-370.
23.
Kheirandish-GozalLBandlaHPGozalD. Montelukast for children with obstructive sleep apnea: results of a double-blind, randomized, placebo-controlled trial. Ann Am Thorac Soc. 2016;13:1736-1741.
24.
GoldbartADGreenberg-DotanSTalA. Montelukast for children with obstructive sleep apnea: a double-blind, placebo-controlled study. Pediatrics. 2012;130:e575-e580.
25.
WhitingPFRutjesAWWestwoodMEet al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529-536.
26.
ShenYXuZShenK. Urinary leukotriene E4, obesity, and adenotonsillar hypertrophy in Chinese children with sleep disordered breathing. Sleep. 2011;34:1135-1141.
27.
KaditisAGAlexopoulosEChaidasKet al. Urine concentrations of cysteinyl leukotrienes in children with obstructive sleep-disordered breathing. Chest. 2009;135:1496-1501.
28.
WangBLiangJ. The effect of montelukast on mild persistent OSA after adenotonsillectomy in children: a preliminary study. Otolaryngol Head Neck Surg. 2017;156:952-954.
29.
CoutrasSWLimjucoADavisKEet al. Sleep endoscopy findings in children with persistent obstructive sleep apnea after adenotonsillectomy. Int J Pediatr Otorhinolaryngol. 2018;107:190-193.
30.
RiveroADurrM. Lingual tonsillectomy for pediatric persistent obstructive sleep apnea: a systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2017;157:940-947.
31.
BerlucchiMSalsiDValettiLet al. The role of mometasone furoate aqueous nasal spray in the treatment of adenoidal hypertrophy in the pediatric age group: preliminary results of a prospective, randomized study. Pediatrics. 2007;119:e1392-e1397.
32.
DemainJGGoetzDW. Pediatric adenoidal hypertrophy and nasal airway obstruction: reduction with aqueous nasal beclomethasone. Pediatrics. 1995;95:355-364.
33.
Al-GhamdiSAManoukianJJMorielliAet al. Do systemic corticosteroids effectively treat obstructive sleep apnea secondary to adenotonsillar hypertrophy?Laryngoscope. 1997;107:1382-1387.
34.
ShaySShapiroNLBhattacharyyaN. Revisit rates and diagnoses following pediatric tonsillectomy in a large multistate population. Laryngoscope. 2015;125:457-461.
35.
DuvalMWilkesJKorgenskiKet al. Causes, costs, and risk factors for unplanned return visits after adenotonsillectomy in children. Int J Pediatr Otorhinolaryngol. 2015;79:1640-1646.
36.
HaarmanMGvan HunselFde VriesTW. Adverse drug reactions of montelukast in children and adults. Pharmacol Res Perspect. 2017;5(5). doi: 10.1002/prp2.341.
37.
Aldea PeronaAGarcia-SaizMSanz AlvarezE. Psychiatric disorders and montelukast in children: a disproportionality analysis of the VigiBase®. Drug Saf. 2016;39:69-78.
38.
CerezaGGarcia DoladeNLaporteJR. Nightmares induced by montelukast in children and adults. Eur Respir J. 2012;40:1574-1575.
39.
KontopantelisESpringateDAReevesD. A re-analysis of the Cochrane Library Data: the dangers of unobserved heterogeneity in meta-analyses. PLoS One. 2013;8(7):e69930.
